These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 30025814)

  • 41. Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control.
    Craig SL; Gault VA; Shiels CE; Hamscher G; Irwin N
    Biochim Biophys Acta Gen Subj; 2021 Aug; 1865(8):129917. PubMed ID: 33964357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.
    Gault VA; Porter DW; Irwin N; Flatt PR
    J Endocrinol; 2011 Mar; 208(3):265-71. PubMed ID: 21212092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
    Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
    Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
    McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
    J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucagon-like peptide-1 and islet lipolysis.
    Sörhede Winzell M; Ahrén B
    Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
    Green BD; Gault VA; O'harte FP; Flatt PR
    Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.
    Irwin N; McClean PL; Hunter K; Flatt PR
    Diabetes Obes Metab; 2009 Jun; 11(6):603-10. PubMed ID: 19515180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic Glu
    Sarnobat D; Moffett RC; Gault VA; Tanday N; Reimann F; Gribble FM; Flatt PR; Irwin N
    Peptides; 2020 Mar; 125():170205. PubMed ID: 31738969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B; Hughes TE
    Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Beneficial metabolic effects of dietary epigallocatechin gallate alone and in combination with exendin-4 in high fat diabetic mice.
    Pathak NM; Millar PJB; Pathak V; Flatt PR; Gault VA
    Mol Cell Endocrinol; 2018 Jan; 460():200-208. PubMed ID: 28754350
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice.
    Moffett RC; Vasu S; Flatt PR
    Biochim Biophys Acta; 2015 Jun; 1850(6):1206-14. PubMed ID: 25688757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
    Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
    Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines.
    Korish AA
    Horm Metab Res; 2014 Jun; 46(6):404-11. PubMed ID: 24627103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The combination of GIP plus xenin-25 indirectly increases pancreatic polypeptide release in humans with and without type 2 diabetes mellitus.
    Chowdhury S; Wang S; Patterson BW; Reeds DN; Wice BM
    Regul Pept; 2013 Nov; 187():42-50. PubMed ID: 24183983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice.
    Irwin N; Hunter K; Flatt PR
    Peptides; 2007 Nov; 28(11):2192-8. PubMed ID: 17884253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
    O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
    Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
    Irwin N; McClean PL; Cassidy RS; O'harte FP; Green BD; Gault VA; Harriott P; Flatt PR
    Diabetes Metab Res Rev; 2007 Oct; 23(7):572-9. PubMed ID: 17315241
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
    Martin CM; Irwin N; Flatt PR; Gault VA
    Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.